Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA(benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...
FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results